Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Open Monoclonal Technology
Builds the first platform for generating human monoclonal antibodies using a transgenic rat
Palo Alto, CA
Contact:
Ron Eastman
www.openmonoclonaltechnology.com
Acquired by: Ligand Pharmaceuticals
Exit date: December 11, 2015
Related News
Developing Knockout Rats for Antibody Discovery
OMT Grants Unlimited Platform Access to CNA Development LLC
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash & Stock
Open Monoclonal Technology Looks to Sell Subsidiaries
